Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions

• DOI: 10.3389/fonc.2024.1367603
• Publication Date: 2024-05-13T12:30:11Z
• Authors: Yangyang Wang; Yongyuan Zhang; Nana Ren; Fangting Li; Lin Lu; Xin Zhao; Zhigang Zhou; Mengyu Gao; Meng Wang
• Keywords: Needle biopsy; Lung biopsy

Objectives The safety and feasibility of repeat biopsy after systemic treatment for non-small cell lung cancer have received extensive attention in recent years. purpose this research was to compare complication rates between initial rebiopsy patients with progressive disease assess risk factors clinical results rebiopsy. Methods study included 113 initially diagnosed who underwent at progression while on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and/or chemotherapy from January 2018 December 2021. We compared the incidence complications analyzed predictors that influenced Results successful rate 88.5% (100/113). With exception two cases where adenocarcinoma changed into small gefitinib treatment, 98 individuals retained their pathological type. secondary EGFR T790M mutation accounts 55.6% acquired resistance. total number 25 (22.1%) 37 (32.7%) pulmonary hemorrhage increased 7.1% 10.6% rebiopsy, pneumothorax 14.2% 20.4%. Compared biopsy, overall complications, parenchymal hemorrhage, by 10.6%, 3.5%, 6.2%, respectively. In all four evaluations (pneumorrhagia, pneumothorax, pleural reaction, complication), there were no significant differences (all p > 0.05). multivariate logistic regression analysis suggested male sex (odds ratio [OR] = 5.064, 0.001), tumor size ≤ 2 cm (OR 3.367, 0.013), EGFR-TKIs 3.633, =0.023), transfissural approach 7.583, 0.026) independent Conclusion displayed a slight, but not significant, elevation Male sex, cm, approach, combined complications.